Menu Search
Equities

ALX Oncology Holdings Inc

ALXO:NSQ

ALX Oncology Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.14
  • Today's Change-0.04 / -1.83%
  • Shares traded389.30k
  • 1 Year change-58.53%
  • Beta1.0211
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year ALX Oncology Holdings Inc's net income fell 30.23% from a loss of 123.48m to a larger loss of 160.81m despite flat revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-74.45%
Return on equity-92.17%
Return on investment-84.76%
More ▼

Cash flow in USDView more

In 2023, cash reserves at ALX Oncology Holdings Inc fell by 26.42m. Cash Flow from Financing totalled 59.29m or -- of revenues. In addition the company used 130.36m for operations while cash from investing totalled 44.66m.
Cash flow per share-3.54
Price/Cash flow per share--
Book value per share3.04
Tangible book value per share3.04
More ▼

Balance sheet in USDView more

ALX Oncology Holdings Inc has a Debt to Total Capital ratio of 7.34%, a higher figure than the previous year's 4.47%.
Current ratio4.39
Quick ratio--
Total debt/total equity0.0792
Total debt/total capital0.0734
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.